A clinical trial update for kisspeptin was recorded on August 26, 2026. The study, titled "Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism," is registered under identifier NCT04648969. It is listed as a Phase 2 trial. Its status has been updated to completed.
Kisspeptin remains an unapproved compound used in research settings. This update reflects only a change in the trial's recorded status on ClinicalTrials.gov. No results, outcomes, or efficacy data are included in this update. No safety findings are described in this record either.
The trial focuses on prolonged pulsatile administration of kisspeptin in individuals with hypogonadotropic hypogonadism. Details about study design, participant outcomes, or specific endpoints are not part of this status update. Readers seeking further information on trial results should consult the official trial registry listing directly once such data are posted.
For more background on kisspeptin, including its research classification and general context, readers can refer to the compound overview.